Company Profile
Liaoning Chengda Biotechnology Co., Ltd., a biopharmaceutical company researches, develops, produces, and sells vaccines in China and globally. It offers inactivated Japanese encephalitis and SPEEDA-rabies vaccines. It also develops rabies vaccine which is in new drug approval stage.
Its portfolio also includes influenza vaccine which is in new drug application stage, recombinant human papillomavirus 15-valent vaccine which is in Phase II clinical stage, and 13-valent pneumococcal polysaccharide conjugate, varicella, and meningococcal A, C, Y and W-135 conjugate vaccines which are in Phase I clinical stage.
Additionally, it is involved in the development of high-dose influenzae vaccine which is in CT approval stage; and vaccines in pre-clinical study stage Including 20-valent pneumococcal polysaccharide conjugate, recombinant zoster, multivalent HFMD, serogroup B meningococcal outer membrane vesicle, and rabies monoclonal antibody.
Incorporated in 2002 and headquartered in Shenyang, China, Liaoning Chengda Biotechnology was formerly known as Liaoning Chengda Biological Technology Limited Company before rebranding in November 2010. The company operates as a subsidiary of Liaoning Cheng Da Co., Ltd.